

The Lancet Summit: Presymptomatic prevention and treatment of neurodegenerative diseases

Preliminary Oral Programme

Wednesday, January 27, 2021

12:00-14:00 Registration

14:00-14:45 **Session 1: Introduction**
Session Chair: TBC

14:00-14:15 **Opening Address**
Elena Becker-Barroso, *The Lancet Neurology Editor, UK*

14:15-14:45 **Overview and Context**
Nick Fox, *University College London, UK*

14:45-15:45 **Session 2: Genetics, cellular pathways, and neuronal vulnerability**
Session Chair: TBC

14:45-15:15 **[INV.01] Overview genetics in neurodegeneration**
John Hardy, *University College London, UK*

15:15-15:45 **[INV.02] Tau biology**
Karen Duff, *University College London, UK*

15:45-16:15 **Refreshment break** | Cambridge

16:15-17:15 **Session 2: Genetics, cellular pathways, and neuronal vulnerability continued**

16:15-16:45 **[INV.03] Parkinson's disease**
Virginia Lee, *University of Philadelphia, USA*

16:45-17:15 **[INV.04] Genetics in ALS**
Ammar Al-Chalabi, *Kings College London, UK*

17:15-18:15 **Welcome reception** | Cambridge

Thursday, January 28, 2021

09:00-10:30 **Session 3: Biomarkers and early diagnosis**
Session Chair: TBC

09:00-09:30 **[INV.05] New biomarkers and an update on NFL**
Henrik Zetterberg, *University College London, UK*

09:30-10:00 **[INV.06] Frontotemporal dementia (FTD)**
Jonathan Rohrer, *University College London, UK*

10:00-10:30 **[INV.07] Searching for oligomers and biomarkers in PD**
David Klenerman, *University of Cambridge, UK*

10:30-11:00 **Refreshment break** | Cambridge

11:00-12:00 **Session 3: Biomarkers and early diagnosis continued**
Session Chair: TBC

11:00-11:30 **[INV.08] Spinocerebellar ataxias and related disorders**
Alexandra Durr, *Institut National de la Santé et de la Recherche Médicale, Paris, France*

11:30-12:00 **[INV.09] Patient's perspective: Sophie Leggatt [London]**

12:00-13:00 **Lunch** | Cambridge

13:00-14:30 **Poster Session 1** | Cambridge

14:30-15:30 **Session 4: Prevention through therapeutics**
Session Chair: TBC

14:30-15:00 **[INV.10] Alzheimer's**
Reisa Sperling, *Harvard Medical School, Boston, USA*

15:00-15:30 **[INV.11] Huntington's disease and HTT lowering genetic therapy trials**
Sarah Tabrizi, *UCL Institute of Neurology, London, UK*

15:30-16:00 **Refreshment break** | Cambridge

16:00-17:00 **Session 4: Prevention through therapeutics I continued**
Session Chair: TBC

16:00-16:30 **[INV.12] Adam Boxer**, *Progressive supranuclear palsy*
UCSF Weill Institute for Neurosciences, San Francisco, USA

16:30-17:00 **[INV.13] Antisense oligonucleotides (ASOs) for Tau and ALS**
Timothy Miller, *Washington University School of Medicine in St. Louis, USA*

Friday, January 29, 2021

09:00-10:30 **Session 5: Prevention II**
Session Chair: TBC

09:00-09:30 **[INV.14] Genome editing for brain diseases and CRISPR**
Feng Zhang, *Broad Institute of MIT and Harvard, USA*

09:30-10:00 **[INV.15] Biogen AD programme**
Samantha Budd, *Biogen, Boston, USA*

10:00-10:30 **Refreshment break** | Cambridge

10:30-11:00 **[INV.16] Antisense oligonucleotides (ASOs) for other ND diseases not including HD, Tau and C9**
Holly Kordasiewicz, *Ionis Pharmaceuticals, San Diego, USA*

11:00-11:30 **[INV.17] Clinical trials in Alzheimer's disease**
Rachelle Doody, *Roche, Geneva, Switzerland*

11:30-12:00

12:00-13:00 **Lunch** | Cambridge

13:00-14:30 **Poster Session 2** | Cambridge

14:30-15:30 **Session 6: Ethical and regulatory considerations**
Session Chair: TBC

14:30-15:00 **[INV.18] Prevention trials**
Billy Dunn, *US FDA, Washington, USA*

15:00-15:30 **[INV.19] Perspective from a middle income country**
Patricia Saidon, *Sociedad Neurologica Argentina, Buenos Aires, Argentina*

15:30-16:00 **Refreshment break** | Cambridge

16:00-17:00 **Session 6: Ethical and regulatory considerations continued**

16:00-16:30 **[INV.20] Patient's perspective**
Eric Minikel and Sonia Vallabh, *Broad Institute, Cambridge, USA*

16:30-17:00 **[INV.21] Innovative trial design and getting drugs approved in Europe and the UK**
Michael Rawlins, *Medicines and Healthcare products Regulatory Agency, UK*

17:00-17:10 **Closing Ceremony**
Elena Becker-Barroso, *The Lancet Neurology Editor, UK*

